AMP-activated protein kinase signaling in metabolic regulation

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1776-1783

  Yun, Chau Long ^a   Zierath, Juleen R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN;

ADIPOSE TISSUE; CELL METABOLISM; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; LIVER METABOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ENERGY METABOLISM; GLUCOSE; HUMANS; ISOENZYMES; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 33745815985     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29044     Document Type: Review

References (112)

1. Klein, S., et al. 2004. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 27:2067-2073.
2. Wing, R.R., et al. 2001. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care. 24:117-123.
3. Hardie, D.G. 2004. The AMP-activated protein kinase pathway: new players upstream and downstream. J. Cell Sci. 117:5479-5487.
4. Carling, D. 2004. The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem. Sci. 29:18-24.
5. Kemp, B.E., et al. 2003. AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31:162-168.
6. Kahn, B.B., Alquier, T., Carling, D., and Hardie, D.G. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15-25.
7. Woods, A., et al. 2005. Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2:21-33.
8. Hurley, R.L., et al. 2005. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280:29060-29066.
9. Hawley, S.A., et al. 2005. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2:9-19.
10. Birnbaum, M.J. 2005. Activating AMP-activated protein kinase without AMP. Mol. Cell. 19:289-290.
11. Hardie, D.G. 2003. Minireview. The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 144:5179-5183.
12. Fryer, L.G.D., Parbu-Patel, A., and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277:25226-25232.
13. Corton, J.M., Gillespie, J.G., Hawley, S.A., and Hardie, D.G. 1995. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229:558-565.
14. Vincent, M.F., Marangos, P.J., Gruber, H.E., and Van den Berghe, G. 1991. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes. 40:1259-1266.
15. Longnus, S.L., Wambolt, R.B., Parsons, H.L., Brownsey, R.W., and Allard, M.F. 2003. 5-Amino-imidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:R936-R944.
16. DeFronzo, R.A., Gunnarsson, R., Bjorkman, O., Olsson, M., and Wahren, J. 1985. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J. Clin. Invest. 76:149-155.
17. Hutber, C.A., Hardie, D.G., and Winder, W.W. 1997. Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. Am. J. Physiol. Endocrinol. Metab. 272:E262-E266.
18. Merrill, G.F., Kurth, E.J., Hardie, D.G., and Winder, W.W. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. Endocrinol. Metab. 273:E1107-E1112.
19. Kurth-Kraczek, E., Hirshman, M., Goodyear, L., and Winder, W. 1999. 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 48:1667-1671.
20. Wright, D.C., Geiger, P.C., Holloszy, J.O., and Han, D.H. 2005. Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca2+-dependent mechanism in slow-twitch rat soleus muscle. Am. J. Physiol. Endocrinol. Metab. 288:E1062-E1066.
21. Derave, W., et al. 2000. Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. Diabetes. 49:1281-1287.
22. Mu, J., Brozinick, J.T., Jr., Valladares, O., Bucan, M., and Birnbaum, M.J. 2001. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell. 7:1085-1094.
23. Fujii, N., et al. 2005. AMP-activated protein kinase a2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle. J. Biol. Chem. 280:39033-39041.
24. Jorgensen, S.B., et al. 2004. Knockout of the α2 but not α1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4- carboxamide-1-β-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279:1070-1079.
25. Barnes, B.R., et al. 2004. The 5′-AMP-activated protein kinase γ3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J. Biol. Chem. 279:38441-38447.
26. Sakamoto, K., et al. 2005. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24:1810-1820.
27. Sano, H., et al. 2003. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278:14599-14602.
28. Larance, M., et al. 2005. Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. J. Biol. Chem. 280:37803-37813.
29. Zeigerer, A., McBrayer, M.K., and McGraw, T.E. 2004. Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol. Biol. Cell. 15:4406-4415.
30. Karlsson, H.K.R., et al. 2005. Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes. 54:1692-1697.
31. Deshmukh, A., et al. 2006. Exercise-induced phosphorylation of the novel Akt substrates AS160 and filamin A in human skeletal muscle. Diabetes. doi:10.2337/db05-1419.
32. Treebak, J.T., et al. 2006. AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes. In press.
33. Zhou, G., et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174. doi:10.1172/JCI200113505.
34. Musi, N., et al. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51:2074-2081.
35. Ruderman, N.B., Saha, A.K., Vavvas, D., and Witters, L.A. 1999. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 276:E1-E18.
36. Trumble, G., Smith, M., and Winder, W. 1995. Purification and characterization of rat skeletal muscle acetyl-CoA carboxylase. Eur. J. Biochem. 231:192-198.
37. Winder, W.W., and Hardie, D.G. 1996. Inactivation of acetyl-CoA carboxylase and activation of AMPactivated protein kinase in muscle during exercise. Am. J. Physiol. Endocrinol. Metab. 270:E299-E304.
38. Winder, W.W., et al. 1997. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J. Appl. Physiol. 82:219-225.
39. Merrill, G.F., Kurth, E.J., Rasmussen, B.B., and Winder, W.W. 1998. Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle. J. Appl. Physiol. 85:1909-1914.
40. Collier, C.A., Bruce, C.R., Smith, A.C., Lopaschuk, G., and Dyck, D.J. 2006. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. doi:10.1152/ajpendo.00272.2005.
41. Holloszy, J.O. 2005. Exercise-induced increase in muscle insulin sensitivity. J. Appl. Physiol. 99:338-343.
42. Zierath, J.R. 2002. Exercise effects of muscle insulin signaling and action. Invited review: exercise training-induced changes in insulin signaling in skeletal muscle. J. Appl. Physiol. 93:773-781.
43. Holloszy, J. 1975. Adaptation of skeletal muscle to endurance exercise. Med. Sci. Sports. 7:155-164.
44. Morino, K., et al. 2005. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J. Clin. Invest. 115:3587-3593. doi:10.1172/JCI25151.
45. Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., and Shulman, G.I. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350:664-671.
46. Petersen, K.F., et al. 2003. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 300:1140-1142.
47. Fisher, J.S., Gao, J., Han, D.-H., Holloszy, J.O., and Nolte, L.A. 2002. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. Endocrinol. Metab. 282:E18-E23.
48. Song, X.M., et al. 2002. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia. 45:56-65.
49. Holmes, B.F., Kurth-Kraczek, E.J., and Winder, W.W. 1999. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. 87:1990-1995.
50. Iglesias, M.A., et al. 2002. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes. 51:2886-2894.
51. Buhl, E.S., et al. 2001. Chronic treatment with 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes. 50:12-17.
52. Long, Y.C., et al. 2005. Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. Diabetologia. 48:2354-2364.
53. Nilsson, E.C., et al. 2006. Opposite transcriptional regulation in skeletal muscle of AMPK gamma 3 R225Q transgenic versus knock-out mice. J. Biol. Chem. 281:7244-7252.
54. Barnes, B.R., et al. 2005. Changes in exercise-induced gene expression in 5′-AMP-activated protein kinase γ3-null and γ3 R225Q transgenic mice. Diabetes. 54:3484-3489.
55. Ojuka, E.O., et al. 2002. Regulation of GLUT4 biogenesis in muscle: evidence for involvement of AMPK and Ca2+. Am. J. Physiol. Endocrinol. Metab. 282:E1008-E1013.
56. Zong, H., et al. 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U. S. A. 99:15983-15987.
57. Bergeron, R., et al. 2001. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metab. 281:E1340-E1346.
58. Puigserver, P., and Spiegelman, B.M. 2003. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24:78-90.
59. Winder, W.W., et al. 2000. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 88:2219-2226.
60. Jorgensen, S.B., et al. 2005. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J. 19:1146-1148.
61. Consoli, A. 1992. Role of liver in pathophysiology of NIDDM. Diabetes Care. 15:430-441.
62. Saltiel, A.R. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 104:517-529.
63. Saltiel, A.R., and Kahn, C.R. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799-806.
64. Lochhead, P.A., Salt, I.P., Walker, K.S., Hardie, D.G., and Sutherland, C. 2000. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 49:896-903.
65. Andreelli, F., et al. 2006. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not by insulin. Endocrinology. 147:2432-2441.
66. Koo, S.-H., et al. 2005. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 437:1109-1111.
67. Shaw, R.J., et al. 2005. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310:1642-1646.
68. Foretz, M., Carling, D., Guichard, C., Ferre, P., and Foufelle, F. 1998. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J. Biol. Chem. 273:14767-14771.
69. Woods, A., et al. 2000. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell. Biol. 20:6704-6711.
70. Zang, M., et al. 2004. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279:47898-47905.
71. Groop, L.C., et al. 1989. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J. Clin. Invest. 84:205-213.
72. Bays, H., Mandarino, L., and DeFronzo, R.A. 2004. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89:463-478.
73. Garton, A.J., et al. 1989. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur. J. Biochem. 179:249-254.
74. Sullivan, J.E., et al. 1994. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 353:33-36.
75. Daval, M., et al. 2005. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280:25250-25257.
76. Villena, J.A., et al. 2004. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 53:2242-2249.
77. Bergeron, R., et al. 2001. Effect of 5-aminoimidazole-4-carboxamide-1- β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 50:1076-1082.
78. Yin, W., Mu, J., and Birnbaum, M.J. 2003. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 278:43074-43080.
79. Detimary, P., Jonas, J.C., and Henquin, J.C. 1995. Possible links between glucose-induced changes in the energy state of pancreatic B cells and insulin release. Unmasking by decreasing a stable pool of adenine nucleotides in mouse islets. J. Clin. Invest. 96:1738-1745.
80. Detimary, P., et al. 1998. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. J. Biol. Chem. 273:33905-33908.
81. Aguilar-Bryan, L., and Bryan, J. 1999. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr. Rev. 20:101-135.
82. Safayhi, H., et al. 1997. L-type calcium channels in insulin-secreting cells: biochemical characterization and phosphorylation in RINm5F cells. Mol. Endocrinol. 11:619-629.
83. Rutter, G.A. 2001. Nutrient-secretion coupling in the pancreatic islet beta-cell: recent advances. Mol. Aspects Med. 22:247-284.
84. Detimary, P., Gilon, P., and Henquin, J.C. 1998. Interplay between cytoplasmic Ca2+ and the ATP/ADP ratio: a feedback control mechanism in mouse pancreatic islets. Biochem. J. 333:269-274.
85. Salt, I.P., Johnson, G., Ashcroft, S.J., and Hardie, D.G. 1998. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem. J. 335:533-539.
86. da Silva Xavier, G., et al. 2000. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. Proc. Natl. Acad. Sci. U. S. A. 97:4023-4028.
87. da Silva Xavier, G., et al. 2003. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371:761-774.
88. Leclerc, I., et al. 2004. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286:E1023-E1031.
89. Zhang, S., and Kim, K.H. 1995. Glucose activation of acetyl-CoA carboxylase in association with insulin secretion in a pancreatic beta-cell line. J. Endocrinol. 147:33-41.
90. Eto, K., et al. 2002. Genetic manipulations of fatty acid metabolism in β-cells are associated with dysregulated insulin secretion. Diabetes. 51(Suppl. 3):S414-S420.
91. Rutter, G.A., Da Silva Xavier, G., and Leclerc, I. 2003. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem. J. 375:1-16.
92. Halaas, J.L., et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:543-546.
93. Kahn, B.B., and Flier, J.S. 2000. Obesity and insulin resistance. J. Clin. Invest. 106:473-481.
94. Unger, R.H., Zhou, Y.-T., and Orci, L. 1999. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. U. S. A. 96:2327-2332.
95. Lee, Y., et al. 2001. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J. Biol. Chem. 276:5629-5635.
96. Muoio, D.M., Dohm, G.L., Fiedorek, F.T., Jr., Tapscott, E.B., and Coleman, R.A. 1997. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes. 46:1360-1363.
97. Kamohara, S., Burcelin, R., Halaas, J.L., Friedman, J.M., and Charron, M.J. 1997. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature. 389:374-377.
98. Haque, M., et al. 1999. Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes. 48:1706-1712.
99. Minokoshi, Y., et al. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 415:339-343.
100. Fruebis, J., et al. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2005-2010.
101. Tomas, E., et al. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. U. S. A. 99:16309-16313.
102. Yamauchi, T., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8:1288-1295.
103. Porte, D., Jr., et al. 1998. Obesity, diabetes and the central nervous system. Diabetologia. 41:863-881.
104. Leibowitz, S.F., and Wortley, K.E. 2004. Hypothalamic control of energy balance: different peptides, different functions. Peptides. 25:473-504.
105. Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., and Baskin, D.G. 2000. Central nervous system control of food intake. Nature. 404:661-671.
106. Andersson, U., et al. 2004. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279:12005-12008.
107. Minokoshi, Y., et al. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 428:569-574.
108. Kim, E.-K., et al. 2004. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J. Biol. Chem. 279:19970-19976.
109. Perrin, C., Knauf, C., and Burcelin, R. 2004. Intra-cerebroventricular infusion of glucose, insulin, and the adenosine monophosphate-activated kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, controls muscle glycogen synthesis. Endocrinology. 145:4025-4033.
110. Viollet, B., et al. 2003. The AMP-activated protein kinase a2 catalytic subunit controls wholebody insulin sensitivity. J. Clin. Invest. 111:91-98. doi:10.1172/JCI200316567.
111. Mu, J., Barton, E.R., and Birnbaum, M.J. 2003. Selective suppression of AMP-activated protein kinase in skeletal muscle: update on 'lazy mice.' Biochem. Soc. Trans. 31:236-241.
112. Barnes, B.R., et al. 2005. 5′-AMP-activated protein kinase regulates skeletal muscle glycogen content and ergogenics. FASEB J. 19:773-779.